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Systematic	Literature	Review:	Diversity	of	Enrollment	in
Multiple	Myeloma	Drug	Trials	Among	Different	Ethnicities
Background	&	Significance
• Multiple	Myeloma	is	a	malignant	disease	characterized	by	the	infiltration	of	bone	
marrow	by	cancerous	plasma	cells.
• Multiple	myeloma	affects	Non	Hispanic	Blacks	(NHB)	66%	more	often	than	Non	
Hispanic	Whites	(NHW)
• Average	cost	of	these	drug	therapies	range	from	$4,000-6000
• The	Purpose:	compare	the	ethnic	diversity	in	enrollment	for	different	drugs	used	to	
treat	multiple	myeloma.	
• Research	Questions
• What	barriers	are	preventing	NHB	from	participating	in	clinical	trials?
• What	can	be	done	to	help	increase	participation?
Methods
• 37	articles	
• Gender	(Male/Female)
• Ethnicity	(African	American,	White,	Asian,	Hispanic)
• Drugs	included:	Thalidomide,	Bortezomib,	Cacrfizomib,	Ixazomib,	
Lenalidomide,	Pomalidomide,	Panobinostat,	Elotuzumab,	Daratumumab
• Clinical	trials	in	phases	2	or	3	
• Excluded:
• 20	sources	missing	African	American	participation	data
• 22	sources	missing	White	participation	data
• Included:
• 15	viable	data	sources	for	NHB	participation
• 17	viable	data	sources	for	NHW	participation
• In	2018,	30,770	new	multiple	myeloma	cases	were	diagnosed	and	of	these	
6,190	were	NHB.	
• 20.11%
• One	sample	T-test	used	to	compare	the	prevalence	amongst	the	black	
population	and	the	average	enrollment	of	blacks	in	the	37		sources	of	data
Results
• T-test	is	significant	.000	<	.05
• One	sample	T-test	value=	20.11
• Mean	NHW	enrollment- 346.9
• Mean	NHB	enrollment-11.73
• Average	%	of	NHW	enrollment- 83%
• Average	%	of	NHB	enrollment- 5.3%
• Large	amount	of	missing	data	from	data	sources-
Discussion	&	Conclusion	
• African	American	cases	make	up	20%	of	the	new	cases	
diagnosed	in	2018.
• Based	on	enrollment	NHB	are	enrolled	to	the	same	degree	as	
the	NHW	population
• What	is	possibly	keeping	them	from	enrolling
• 25%	of	the	population	in	poverty	is	made	of	African	
American.	
• Cost	of	these	drugs
• Locations	of	where	therapy	is	done	(US/International)
• Personal	view	point	of	patient
• Pharmaceutical	company	reporting	and	research	
• Not	required	to	report	
• Could	be	altering	the	collected	data
• Out	of	37	sources	of	data	only	4	were	either	not	
funded	or	did	not	state	pharmaceutical	funding	for	
their	research.
• More	research	is	needed	to	determine	why	the	most	affected	
population	isn’t	properly	represented	in	drug	clinical	trials.
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